71 results about "Fibronectins" patented technology

The invention discloses a double-structural-domain recombinant human fibronectin, the sequence of which is shown as SEQ ID NO.3, and the double-structural-domain recombinant human fibronectin is formed by fusing a collagen binding structural domain and a cell binding structural domain of human fibronectin. The invention also provides a recombinant expression vector containing the protein coding gene and a host cell. The protein is efficiently expressed through eukaryotic cells and engineering bacteria escherichia coli, and a fermentation and purification process suitable for an industrial scale is established in a matched manner. Functional experiments prove that compared with commercially available fibronectin products with a single structural domain, the double-structural domain recombinant human chemical fibronectin disclosed by the invention can remarkably promote proliferation, migration, adhesion and differentiation activity of human skin fibroblasts, and has wide application potential in the fields of skin repair, skincare and biomedical materials.

The invention discloses beta-glucan medical beauty essence with a barrier repairing function, and belongs to the technical field of cosmetics. According to the invention, the fibronectin is wrapped with beta-glucan, then the fibronectin is secondarily wrapped with a thermosensitive film, and active ingredients are slowly released through hot compress, so that the transdermal amount is increased. Beta-glucan, fibronectin and callicarpa nudiflora extract are cooperated, triple anti-inflammatory repair is achieved, percutaneous water loss is reduced, and a long-term repair effect is achieved.

The invention discloses an antioxidant repairing composition and application thereof and cosmetics, the antioxidant repairing composition comprises the following components in parts by mass: 32-48 parts of a Chinese herbaceous peony extract combined factor, 8-12 parts of a radix sophorae flavescentis extract combined factor, 1.6-2.4 parts of zinc gluconate and 1.6-2.4 parts of a fibronectin factor, through the mutual cooperation of the four components, the antioxidant effect of the skin can be effectively improved, the damage of oxidative stress and inflammation to the skin can be effectively reduced, and the cell regeneration effect of the skin is promoted; belongs to the technical field of cosmetics.

The present invention relates to a composition comprising the compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient for the prevention or treatment of fibrotic diseases. The composition according to the present invention inhibits the expression of collagen type 1 (COL1A1) or fibronectin and thus can be advantageously used as a composition for the prevention or treatment of fibrotic diseases.

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.

The present invention relates to a composition for preventing or treating liver fibrosis or liver fibrosis-associated diseases, comprising a USP10 inhibitor as an active ingredient. The composition comprising a USP10 inhibitor as an active ingredient, of the present invention, was confirmed to inhibit the activity and / or expression levels of collagen and fibronectin, which are associated with liver fibrosis. Thus, the composition can be used to enhance the effect of treating liver fibrosis and / or liver fibrosis-associated diseases.

The present invention produces a large number of mesenchymal stem cells in a short time in a culture medium containing no heterologous components by including a step of culturing a cell population containing mesenchymal stem cells in the presence of a fibronectin fragment.

Mesothelin-binding fibronectin type III (Fn3) domain proteins having improved mesothelin binding characteristics are described.

Protein scaffolds and scaffold libraries based on a fibronectin type III (FN3) domain with an alternative binding surface design, isolated nucleic acids encoding the protein scaffolds, vectors, host cells, methods of making thereof, and uses as therapeutic molecules for treatment and diagnosis of diseases and disorders.

The present application relates to an Intercellular Adhesion Molecule 2 (ICAM-2) binding polypeptide. This ICAM-2 binding polypeptide comprises a fibronectin type III (FN3) domain having at least one modified loop amino acid sequence and, optionally, a modified beta strand. The one or more modified loop sequences, together with the optional beta strand modifications, enable selective binding to ICAM-2. Also disclosed are conjugates that include the ICAM-2 binding polypeptide, polynucleotides encoding the same, and methods of using these materials for inhibiting transplant organ rejection as well as treatment of hypertension and cancer.

The invention relates to sesquiterpenoids Oxyphyllene F and Oxyphyllene G which are separated from fructus alpiniae oxyphyllae and application of the sesquiterpenoids Oxyphyllene G. Experimental research finds that the two compounds can inhibit the expression of fibronectin, type I collagen and alpha-smooth muscle actin in rat renal tubular duct epithelial cells induced by TGF-beta1, have anti-renal fibrosis activity, and can be used for preparing anti-renal fibrosis drugs. The fructus alpiniae oxyphyllae can be effectively used for preparing kidney protection drugs, the preparation method is good in reproducibility, the purity of the obtained compound is high, further pharmacological and clinical research on the compound is facilitated, the medicinal value of the fructus alpiniae oxyphyllae is expanded, and the economic and social benefits are huge.

The invention belongs to the technical field of biomedical treatment, and particularly relates to recombinant human fibronectin max-rhFN as well as a preparation method and application thereof. The amino acid sequence of the recombinant human fibronectin mat-rhFN is as shown in SEQ ID NO. 2. The molecular weight of the recombinant human fibronectin mat-rhFN provided by the invention is about 130kDa, the purity is higher than 95%, and the endotoxin content is relatively low. Through cell biology detection, the recombinant human fibronectin mat-rhFN provided by the invention is good in activity, has the effects of promoting cell proliferation and cell adhesion, and also has a good protection effect in a keratinocyte anti-SDS stimulation test, and meanwhile, the recombinant human fibronectin mat-rhFN provided by the invention has a remarkable interaction with collagen.

The present invention relates to the interaction of the protein HMCN1 (hemicentin 1 or fibulin 6) as a substrate of the protease ADAMTS12 (a disintegrin and metalloproteinase with thrombospondin motif 12 protein) in the pathogenesis of chronic kidney and heart diseases, and in particular chronic renal insufficiency and renal fibrosis, and heart failure and cardiac fibrosis, respectively. The present invention further relates to methods for identifying compounds that bind to and / or inhibit the protease ADAMTS12, as well as pharmaceutical compositions for use in the treatment of kidney diseases, in particular pharmaceutical compositions comprising active substances that inhibit the cleavage and digestion of hemicentin 1 by the metalloprotease ADAMTS12 or the interaction of hemicentin 1 with ADAMTS12.

The present invention relates to a composition for preventing, alleviating or treating fibrosis, the composition comprising bentonite as an active ingredient. Bentonite is highly effective in reducing a disease activity index, inhibiting shortening of colon length, regulating the expression level of a gene related to intestinal fibrosis, reducing a collagen deposition site in intestinal tissue, reducing the expression level of fibronectin and collagen proteins in intestinal tissue in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of ɑ-smooth muscle actin (ɑ-SMA) and collagen proteins in an intestinal fibrosis cell model induced by TGF-β, and is thus expected to be useful as a composition for preventing, alleviating, or treating intestinal fibrosis.

Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.

Mesothelin-binding fibronectin type III (Fn3) domain proteins having improved mesothelin binding characteristics are described.

The invention relates to the technical field of protein engineering, particularly discloses a human-like fibronectin and a skin filling composition thereof, and provides a recombinant human-like fibronectin, the amino acid sequence of which is as shown in SEQ ID No.1, and the recombinant human-like fibronectin can promote adhesion or migration of skin fibroblasts, so that the human-like fibronectin can be used as a skin filling composition. And the lasting stability of the molecular structure can be maintained in subcutaneous tissues. The skin filling composition containing the recombinant human-like fibronectin can provide supporting and filling functions through subcutaneous injection, so that the purpose of correcting wrinkles is achieved.

The application discloses a recombinant humanized collagen composition for resisting HPV infection and a preparation method thereof. The composition comprises the following components in percentage by mass: 30-45% of a recombinant humanized collagen fusion protein, 30-40% of probiotics and 20-35% of glycogen. The recombinant humanized collagen fusion protein comprises, from N-terminal to C-terminal, a recombinant humanized collagen fragment and a human fibronectin fragment connected in sequence. The recombinant humanized collagen fragment and the human fibronectin fragment are connected by a linker. The recombinant humanized collagen fusion protein in the composition can promote the adhesion and colonization of the probiotic composition to the vaginal epithelial cells, rapidly improve the microbial environment of the vagina and effectively enhance the resistance of the vagina to harmful bacteria and viruses.

Disclosed are compositions and methods for their use that can be used in cosmetic applications. The composition can include an effective amount of a Centella asiatica stem cells to reduce the activity of hyaluronidase in skin, an effective amount of tetradecyl aminobutyroylvalylamino butyric urea trifluoroacetate or Alpinia galanga leaf extract to promote the production of hyaluronic acid in skin, an effective amount of tripeptide-1 to promote the production of fibronectin and laminin in skin, and a dermatologically acceptable vehicle.

The invention relates to the technical field of biology, in particular to a fibronectin-XVII type collagen fusion protein as well as a preparation method and application of the fibronectin-XVII type collagen fusion protein. The fusion protein comprises at least one XVII type collagen functional domain fragment and at least one fibronectin cell binding domain fragment, the novel COLXVII-FN fusion protein is obtained by carrying out recombinant expression on an XVII type collagen helical region functional fragment and a fibronectin structural domain fragment by utilizing a genetic engineering technology. Through in-vitro cell verification and efficacy test, the fusion protein shows the dual efficacy of collagen and fibronectin, and has obvious cell adhesion promotion and anti-inflammatory activity, the cell adhesion promotion can enhance the intercellular connection, and the anti-inflammatory activity of the fusion protein is helpful to alleviate skin inflammation response. The compound also shows the activity of promoting cell proliferation and adhesion, and accelerates the renewal of cells; in conclusion, the fusion protein has wider application potential in the fields of skin care products, cosmetics, medicines, biomedical materials and the like.

The invention discloses a composition and application thereof in preparation of a product with acne removing and / or repairing functions, and the composition is prepared from the following components in parts by mass: 0.1-0.5 part of fibronectin, 1-3 parts of a bacillus coagulans fermentation product, 0.5-5 parts of a rehmannia root extract, 1-5 parts of a lotus corniculatus seed extract and 0.5-2 parts of ecological nutrients. Through reasonable compounding of fibronectin, a bacillus fermentation product, the rehmannia root extract, the lotus corniculatus seed extract and ecological nutrients, a multi-target synergistic effect is embodied and played, a remarkable synergistic effect of 1 + 1 > 2 is achieved, the acne removing and repairing effects are excellent, skin redness is eliminated, skin grease secretion is inhibited, bacteria and inflammation are resisted, acnes can be rapidly removed, and the acne removing and repairing effects are good. The composition can gently repair the damaged skin barrier, regulate the micro-ecological balance of the skin, improve the skin resistance and reduce acne recurrence.

This invention belongs to the field of biomedicine, specifically relating to the application of APOL2 (Apolipoprotein L2) inhibitors in the preparation of products for treating liver fibrosis. The inventors isolated a series of natural tetrodopane-type diterpenes from *Euphorbia pekinensis*, a plant in the Euphorbiaceae family. Anti-liver fibrosis-related activity tests on this series of diterpenes revealed that they significantly inhibited the expression of fibronectin, type I collagen, and α-smooth muscle actin in LX-2 cells. In animal studies, their therapeutic effect was superior to that of pirfenidone, a phase II clinical trial drug for treating liver fibrosis, and they showed no significant toxicity. Mechanistic studies showed that TD1 is an APOL2 inhibitor, and knocking out APOL2 protein in vivo can alleviate the progression of liver fibrosis. In summary, this series of tetrodopane-type diterpenes, especially TD1, shows promise as a candidate drug for treating liver fibrosis and provides a new target for researching novel drugs for treating liver fibrosis.

The application discloses a NEED short peptide modified polylactic acid implant material and a preparation method and application thereof, and relates to the technical field of biomedical materials. The preparation method of the NEED short peptide modified polylactic acid implant material provided by the application is as follows: an interface composed of polylactic acid material is constructed on the surface of an implant material substrate, the interface is activated, and the NEED short peptide is fixed on the interface. The polylactic acid implant material prepared by the application utilizes the interface composed of the polylactic acid material and the NEED short peptide with negative electricity to enhance the adhesion stability of adhesion proteins such as fibronectin and to enhance the subsequent cell adhesion response, thereby promoting cell adhesion and implant material integration. The material can be widely applied to the fields of degradable vascular stents, bone repair materials, dental implants, tissue engineering stents and nanofiber membranes, and can also provide a new technical scheme for interface functionalization of implant materials in a metabolic abnormal environment, and has a wide application prospect.

The invention discloses a high-performance tissue sealant as well as a preparation method and application thereof, and relates to the technical field of medical materials. The tissue sealant is prepared from the following raw materials: amino-containing protein, a multi-arm polyethylene glycol derivative and an optional multi-amino polymer, wherein the amino-containing protein comprises at least one of lactoferrin, phycocyanin, whey protein, beta-lactoglobulin, cytochrome C, recombinant collagen, recombinant fibronectin and alpha-lactalbumin. The sealant provided by the invention has the characteristics of rapid gelling, strong adhesion, high mechanical strength, low swelling, antibacterial property and the like, can realize efficient tissue wound sealing, hemostasis and repair in a wet complex environment, is simple and convenient to prepare, safe in material source and good in biocompatibility, is suitable for being used in various wound scenes, and has wide application prospects. Good application prospects are realized.

The application discloses a double-domain recombinant humanized fibronectin, the sequence of which is shown as SEQ ID NO. 3, which is composed of the collagen binding domain and the cell binding domain of human fibronectin. The application also provides a recombinant expression vector and a host cell containing the gene coding the protein. The protein is efficiently expressed by eukaryotic cells and engineered Escherichia coli, and a fermentation and purification process suitable for industrial scale is established. Functional experiments prove that, compared with the single-domain commercial fibronectin product, the double-domain recombinant humanized fibronectin of the application can significantly promote the proliferation, migration, adhesion and differentiation activity of human skin fibroblasts, and has wide application potential in the fields of skin repair, beauty and skin care and biomedical materials.

The application discloses a lignan compound and a preparation method and application thereof, and relates to the technical field of medicines. The application specifically relates to four lignan small-molecule compounds with the same planar structure, which are separated from amber, and include two pairs of enantiomers (+)-6 / (-)-6 and (+)-7 / (-)-7. The compound structures are as follows: In a renal fibrosis model experiment, the lignan compound provided by the application can inhibit the expression of proteins related to renal fibrosis, such as alphaSMA protein, type I collagen protein and fibronectin, in NRK-52E cells induced by transforming growth factor beta 1, which indicates that the lignan compound provided by the application has the use of preparing medicines for preventing and treating renal fibrosis.

Provided are a recombinant human fibronectin (FN) having a complex function of soothing, a preparation method therefor, and the use thereof. Said recombinant human fibronectin has an amino acid sequence shown as SEQ ID NO.1. By adding a hyaluronic acid interaction segment of human fibronectin while retaining main segments of human fibronectin cell adhesion and integrin receptor interaction, and linking the two domains by means of a flexible "linker" amino acid sequence GGS, the recombinant human FN protein having the complex function is constructed. While possessing core characteristics of traditional recombinant fibronectins, the present recombinant human fibronectin also exhibits an effect of soothing cell irritations. Therefore, the prepared recombinant human fibronectin is expected to exhibit a good effect in soothing skin irritation in the field of functional active skincare products.

The invention belongs to the technical field of daily skin care products, and relates to a biological agent with a bionic ECM structure and application of the biological agent in the field of skin aging resistance. The biological agent with a bionic ECM structure is prepared by simulating components of natural ECM of skin and mainly comprises fibronectin rh FN-LN, collagen, glycoprotein, serum albumin, a polyamino acid polysaccharide condensation compound, mannitol, trehalose and auxiliary materials. The auxiliary materials comprise elastin, decapeptide-4 and the like. An elastinase inhibition ratio test and a human skin fibroblast proliferation test prove that the biological agent with the bionic ECM structure has the effects of repairing, resisting aging and improving skin compactness.

The invention provides a human fibronectin-collagen recombinant fusion protein for lip care. The fusion protein structurally comprises a fibronectin part, a connecting peptide and a collagen part, wherein the amino acid sequence of the fibronectin part is as shown in SEQ ID NO. 1, and the amino acid sequence of the collagen part is as shown in SEQ ID NO. 2. Functional regions of human fibronectin and human III-type collagen are specifically intercepted, and the fibronectin and the collagen are connected through the connecting peptide, so that the high-stability compound protein is obtained, the expression quantity can reach 11.40 g / L, cell adhesion and cell proliferation can be promoted, and the human III-type collagen can be used for preparing the high-stability compound protein. The lip care product has the effects of moisturizing, repairing, nourishing, brightening the skin color of the lips and the skin color around the lips, improving the softness of the lips, fading cheilogramma, improving the gloss around the lips, improving the darkness around the lips and improving the fullness of the lips, and can be used as a raw material of a skin care product.